Copenhagen, 31 August 2007 - On 13 August 2009, NeuroSearch A/S (NEUR)
increased its share capital with the issue of 345,238 new shares of DKK 20
nominal value each. The shares were issued and subscribed for by
GlaxoSmithKline (GSK) at a market price of DKK 107.84 per share upon exercise
of an option to NeuroSearch to issue shares under the existing development
alliance with GSK.

On 25 August 2009, NeuroSearch increased its share capital further with the
issue of 618,562 new shares of DKK 20 nominal value each. The shares were
issued and subscribed for by Johnson & Johnson Development Corporation at a
market price of DKK 120.35 per share as an equity investment in NeuroSearch
related to the signing of a drug discovery and drug development alliance
between NeuroSearch and Janssen Pharmaceutica.

Pursuant to section 6 of Executive Order no. 1273 of 16 December 2008 on
Issuers' Disclosure Obligations, it is hereby announced that at the end of
August 2009, the nominal value of NeuroSearch share capital is DKK 344,756,600
distributed on 17,237,830 shares of DKK 20 nominal value each, and
corresponding to 344,756,600 votes.


Flemming Pedersen
CEO


Contact persons:

Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor & Capital Market
Relations, telephone: +45 4017 5103



About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on NASDAQ
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Janssen Pharmaceutica, Eli Lilly and Company and
GlaxoSmithKline (GSK), and license collaboration with Abbott. The drug pipeline
comprises seven clinical (Phase I-III) development programmes:
Huntexil™(Pridopidine) for Huntington's disease (Phase III), tesofensine for
obesity (Phase III ready), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat dyskinesias
in Parkinson's disease (Phase Ib), ABT-560 for the treatment of cognitive
dysfunctions (Phase I) in collaboration with Abbott, NSD-788 for anxiety (Phase
I) and NSD-721 for social anxiety disorder (Phase I). In addition, NeuroSearch
has a broad portfolio of preclinical drug candidates and holds equity interests
in several biotech companies.

fonds.42-09 - share capital status_august - uk.pdf